ESCRS - Supplement: Optimizing Presbyopia Correction and Astigmatism Management with Modern Lens Technologies
Supplements

Supplement: Optimizing Presbyopia Correction and Astigmatism Management with Modern Lens Technologies

Supplement: Optimizing Presbyopia Correction and Astigmatism Management with Modern Lens Technologies

According to the 2020 ESCRS Clinical Trends Survey, since 2016, there has been a 6% increase in implantation of toric intraoc-ular lenses (IOLs) during cataract surgery, whereas implantation of presbyopia-correcting IOLs has re-mained stable during that time period (Figure 1).The survey also indicated that there is increased interest in extended depth of focus IOLs, at the ex-pense of trifocal and bifocal IOLs (Figure 2).When respondents were asked about their most current procedure to manage astigmatism in a pa-tient receiving monofocal IOLs during cataract sur-gery, 80.8% used a toric IOL in patients with 2.50 D of astigmatism; in patients with 1.75 D of astigma-tism, 66% used a toric IOL; and in patients with 1.25 D of astigmatism 46% used a toric IOL, which is ba-sically the threshold.

Tags: glaucoma
Latest Articles
Committing to a More Equitable Ophthalmology

Charity Committee enhances ESCRS’s reputation as a socially responsible society.

Read more...

Virtual Community Unites Ukrainian Eye Specialists

Microlearning platform proves vital to saving eyes and lives in areas of conflict.

Read more...

ESCRS Survey Shifts Industry Dial

Annual survey reveals trends and issues regarding the digital OR.

Read more...

Always Measure the Epithelium!

Epithelium thickness mapping key to better refractive outcomes.

Read more...

Brave New World of AI

More applications for anterior segment anticipated.

Read more...

Advancing Vision Research

National Eye Institute initiatives encourage AI-based innovations and data interoperability.

Read more...

Best Candidates for Phakic EDOF IOLs?

Patient profile suggests limits for phakic EDOF approach.

Read more...

Knowing Iris Repair: Iris Repair with Prosthetic Devices

New devices on the market expand available options when iris tissue is insufficient.

Read more...

Targeting the Kallikrein-Kinin System to Treat DME

Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.

Read more...

Faricimab VOYAGER Study

Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.

Read more...